Oral physostigmine in Alzheimer's disease: effects on norepinephrine and vasopressin in cerebrospinal fluid and plasma.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Biological Psychiatry

• Publication date

  1995-10-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0006-3223(94)00377-FPMID 8562665
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neurobiology of Cerebrospinal Fluid 1

  2012cited by this paper
• Pharmacological analysis of a cholinergic receptor mediated regulation of brain norepinephrine neurons

  2005cited by this paper
• Role of brain acetylcholine in vasopressin release during osmotic stimulation and hemorrhage

  2004cited by this paper
• A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group.

  1994cited by this paper
• A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease

  1994cited by this paper
• Detection by in vivo microdialysis of nicotine-induced norepinephrine secretion from the hypothalamic paraventricular nucleus of freely moving rats: dose-dependency and desensitization.

  1993cited by this paper
• Concentration of monoamines and their metabolites in the cerebrospinal fluid from patients with senile dementia of the Alzheimer type and vascular dementia of the Binswanger type

  1992cited by this paper
• Muscarinic cholinergic control of vasopressin secretion from the acute hypothalamoneurohypophysial explant.

  1991cited by this paper
• Loss of high‐affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: Implications for the failure of cholinergic replacement therapies

  1991cited by this paper
• Correlation between plasma physostigmine concentrations and percentage of acetylcholinesterase inhibition over time after controlled release of physostigmine in volunteer subjects.

  1991cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1991cited by this paper
• Differential effects of aging on neuroendocrine responses to physostigmine in normal men.

  1990cited by this paper
• Sensitive analysis of plasma physostigmine levels using dual-cell electrochemistry in the redox mode.

  1990cited by this paper
• Neuroendocrine actions of nicotine and of exposure to cigarette smoke: medical implications.

  1989cited by this paper
• Yohimbine increases cerebrospinal fluid and plasma norepinephrine but not arginine vasopressin in humans.

  1989cited by this paper
• Combined administration of physostigmine and clonidine to patients with dementia of the Alzheimer type: a pilot safety study.

  1989cited by this paper
• Oral contraception and genital tract malignancy.

  1989cited by this paper
• Increased plasma and cerebrospinal fluid norepinephrine in older men: differential suppression by clonidine.

  1988cited by this paper
• The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes

  1988cited by this paper
• Carbachol-induced increases in locus coeruleus spontaneous activity are associated with an altered pattern of response to sensory stimuli.

  1987cited by this paper
• Antagonists discriminate muscarinic excitation and inhibition in sympathetic ganglion.

  1987cited by this paper
• Clonidine decreases plasma and cerebrospinal fluid arginine vasopressin but not oxytocin in humans.

  1987cited by this paper
• Effects of oral physostigmine in Alzheimer's disease

  1987cited by this paper
• Muscarinic cholinergic receptor subtypes in normal human brain and Alzheimer's presenile dementia.

  1987cited by this paper
• Peripheral sympathectomy and adrenal medullectomy do not alter cerebrospinal fluid norepinephrine.

  1986cited by this paper
• Effect of cholinergic antagonists on basal and osmotically stimulated vasopressin release in compartmentalized hypothalamo-neurohypophysial explants.

  1986cited by this paper
• Acetylcholine hyperpolarizes central neurones by acting on an M2 muscarinic receptor

  1986cited by this paper
• Cerebrospinal fluid vasopressin, oxytocin, somatostatin, and beta-endorphin in Alzheimer's disease.

  1986cited by this paper
• Age differences in plasma norepinephrine kinetics in humans.

  1986cited by this paper
• Hypertension associated with oral administration of physostigmine in a patient with Alzheimer's disease.

  1986cited by this paper
• Cerebrospinal Fluid Vasopressin, Oxytocin, sopressin, Oxytoc in Alzheimer's Diseasβ-Endorphin

  1986cited by this paper
• Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation.

  1985cited by this paper
• Norepinephrine and MHPG levels in CSF and plasma in Alzheimer's disease.

  1984cited by this paper
• Regulation of locus coeruleus neurons and splanchnic, sympathetic nerves by cardiovascular afferents.

  1984cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• Vasopressin-like peptides in the rat brain: immunologic and chromatographic behavior and their response to water deprivation.

  1983cited by this paper
• Alzheimer's disease: a disorder of cortical cholinergic innervation.

  1983cited by this paper
• CSFandplasma vasopressmconcentrations in dementia

  1983cited by this paper
• Memory enhancement with oral physostigmine in Alzheimer's disease.

  1983cited by this paper
• Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain.

  1982cited by this paper
• Selective loss of neurones of origin of adrenergic projection to cerebral cortex (nucleus locus coeruleus) in senile dementia.

  1981cited by this paper
• Norepinephrine in Cerebrospinal Fluid Basic Studies, Effects of Drugs and Disease

  1980cited by this paper
• Cholinergic stimulation of norepinephrine release in man. Evidence of a sympathetic postganglionic axonal lesion in diabetic adrenergic neuropathy.

  1979cited by this paper
• Cholinergic involvement in osmotic control of vasopressin release by the organ-cultured rat hypothalamo-neurohypophyseal system.

  1979cited by this paper
• Simultaneous liquid-chromatographic determination of 12 common sedatives and hypnotics in serum.

  1978cited by this paper
• Comparison of double- and single-isotope enzymatic derivative methods for measuring catecholamines in human plasma.

  1978cited by this paper
• Norepinephrine and 3-methoxy-4-hydroxyphenyl glycol gradients in human cerebrospinal fluid.

  1977cited by this paper
• Relationship between norepinephrine in blood and cerebrospinal fluid in the presence of a blood cerebrospinal fluid barrier for norepinephrine

  1977cited by this paper
• The Pharmacological Basis of Therapeutics

  1976cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper
• Prolonged activation of tyrosine hydroxylase in noradrenergic neurones of rat brain by cholinergic stimulation

  1975cited by this paper
• Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection.

  1971cited by this paper
• Improvement of Learning in the Aged by Modification of Autonomic Nervous System Activity

  1970cited by this paper
• Blood-Brain Barrier for Adrenaline

  1959cited by this paper

• Detection of Dementia Disease using CNN Classifier by Comparing with ANN Classifier

  2022cites this paper
• Electrochemical sensor for neurotransmitters at physiological pH using a heterocyclic conducting polymer modified electrode.

  2012cites this paper
• Simultaneous determination of catecholamines and their metabolites related to Alzheimer's disease in human urine.

  2011cites this paper
• Profiling analysis of catecholamines and polyamines in biological samples

  2011cites this paper
• Restoration of Norepinephrine-Modulated Contextual Memory in a Mouse Model of Down Syndrome

  2009cites this paper
• Choroid Plexus and CSF in Alzheimer‚Äôs Disease: Altered Expression and Transport of Proteins and Peptides

  2005cites this paper
• The role of norepinephrine in the pathophysiology of cognitive disorders: potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's disease.

  1999cites this paper